Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 234,040 | 132,565 | 77,798 | 15,325 | 413 |
| Cost of Goods | 74,363 | 51,667 | 23,410 | 4,769 | N/A |
| Gross Profit | 159,677 | 80,898 | 54,388 | 10,556 | 413 |
| Operating Expenses | 476,817 | 423,523 | 329,474 | 284,487 | 164,872 |
| Operating Income | -316,777 | -341,958 | -274,676 | -273,162 | -164,459 |
| Interest Expense | 19,356 | 16,474 | 6,273 | 15,148 | 0 |
| Other Income | 12,447 | 2,710 | -361 | 3,601 | 5,030 |
| Pre-tax Income | -323,686 | -355,722 | -281,310 | -284,709 | -159,429 |
| Income Tax | 300 | 700 | N/A | -2,620 | N/A |
| Net Income Continuous | -323,986 | -356,422 | -281,310 | -282,089 | -159,429 |
| Net Income | $-323,986 | $-356,422 | $-281,310 | $-282,089 | $-159,429 |
| EPS Basic Total Ops | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
| EPS Basic Continuous Ops | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
| EPS Diluted Total Ops | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
| EPS Diluted Continuous Ops | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
| EPS Diluted Before Non-Recurring Items | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
| EBITDA(a) | $-213,943 | $-233,319 | $-253,484 | $-253,609 | $-164,187 |